• AbbVie's Allergan Aesthetics reported improved facial appearance satisfaction in two Phase 4 studies of adults taking GLP-1 medications for weight loss.
• HARMONY IN DIVERSITY combined fillers, a neurotoxin and skincare, significantly improving satisfaction with facial appearance, skin quality and psychosocial function.
• HALO interim results showed high satisfaction with facial appearance following filler treatment, including natural-looking results.
• Most treatment-related adverse events in both studies were mild and nonserious.
• Results were presented at the American Society for Dermatologic Surgery annual meeting, held Nov. 5-8, 2026, in San Diego.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611081245PR_NEWS_USPR_____CG91311) on November 08, 2026, and is solely responsible for the information contained therein.